The scoop:Krystal Biotech’s Vyjuvek is not only thefirsttreatment for the rare and devastating skin disease dystrophic epidermolysis bullosa (DEB), but it's also the first-ever topical gene therapy approved by the FDA. The medicine comes in a gel form that DEB patients can use...
targets and inhibits tumor angiogenesis-inducing VEGFR2. PharmAbcine is conducting a Phase 2 clinical trial on olinvacimab in patients with Avastin-refractory rGBM in the U.S. andAustralia. In addition, Phase1btrials on olinvacimab plus PD-1 antibody Keytruda ...